

ATTORNEY DOCKET NO. 04156.0012U1  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2

In re Application of	)	
	)	
SANDIG, et al.	)	Art Unit: unassigned
	)	
Application No. 10/530,224	)	Examiner: unassigned
	)	
International Filing Date: October 6, 2003	)	Confirmation No. unassigned
	)	
For: HIGH YIELD HETEROLOGOUS	)	
EXPRESSION CELL LINES FOR	)	
EXPRESSION OF GENE PRODUCTS	)	
WITH HUMAN GLYCOSYLATION	)	
PATTERN	)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.


**ATTORNEY DOCKET NO. 04156.0012U1**  
**Application No. 10/530,224**

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.

  
Lizette M. Fernandez  
Registration No. 46,694

NEEDLE & ROSENBERG, P.C.  
Customer Number 23859  
(678) 420-9300  
(678) 420-9301 (fax)

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

  
Lizette M. Fernandez

7/19/05  
Date

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)				Complete if Known			
				Application Number	10/530,224		
				Intl. Filing Date	October 16, 2003		
				First Named Inventor	Sandig et al.		
				Group Art Unit	Unassigned		
				Examiner Name	Unassigned		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
	A1	WO 00/63410	10/26/00	Einstein Coll Med; Mass Inst Tech.			
	A2	WO 02/08409	01/31/02	Ow			
<b>NON-PATENT DOCUMENTS</b>							
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	A3	Fernandez and Lolis Structural studies of chemokines that inhibit HIV-1 entry. Antivir Chem Chemother. 2001;12 Suppl 1:43-49.					
	A4	Feng et al, Site-specific chromosomal integration in mammalian cells: highly efficient CRE recombinase-mediated cassette exchange. J Mol Biol. 1999 Oct 1;292(4):779-785.					
	A5	Fussenegger, et al., Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotechnol. 1999 Jan;17(1):35-42.					
	A6	Esperet et al. Non-erythroid genes inserted on either side of human HS-40 impair the activation of its natural alpha-globin gene targets without being themselves preferentially activated. J. Biol. Chem. 2000;275(33):25831-25839					
	A7	Garber, Biotech industry faces new bottleneck. Nat Biotechnol. 2001 Mar;19(3):184-185.					
	A8	Groth et al. A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A. 2000 May 23;97(11):5995-6000.					
	A9	Hollenberg and Gelissen, Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997 Oct;8(5):554-560.					
	A10	Karreman et al., On the use of double FLP recognition targets (FRTs) in the LTR of retroviruses for the construction of high producer cell lines. Nucleic Acids Res. 1996 May 1;24(9):1616-1624.					
	A11	Noguchi et al., Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem (Tokyo). 1995 Jan;117(1):59-62.					
	A12	Schlake T, Bode J. Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry. 1994 Nov 1;33(43):12746-51.					
	A13	Trinh et al., Site-specific and directional gene replacement mediated by Cre recombinase. J Immunol Methods. 2000 Oct 20;244(1-2):185-193.					
Examiner Signature:				Date Considered:			
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							